Kazakhstan Pharmaceutical Market Report 2022 by PROXIMA RESEARCH INTERNATIONAL

#Kazakhstan, like many other countries, has faced unprecedented challenges in recent years. A pandemic, external political events and internal political issues affected the economy.

As a result, the physical volume of GDP increased only 3% from the corresponding quarter in 2021 to the III quarter of 2022, better than the III quarter of 2020, but worse than before the pandemic.

The national currency's purchasing power is decreasing, the inflation rate is rising (20.3% in December 2022 compared to December 2021) and the consumer price index is rising (120.3% in December 2022 compared to December 2021), canceling out the growth in per capita income (149,058 tenge in November 2022).

Of course, all these events, to one degree or another, affected the pharmaceutical market. As a result, according to PharmXplorer's market research system, its physical and monetary volume decreased at the end of 2022. Compared to last year, it has shrunk by 0.8% and 8.2%, respectively, in national currency to 863 billion tenge, and in US dollars to 1,872 million.

Its volume decreased by 1.4%, from 626 million packs in 2021 to 618 million packs in 2022. 

Meanwhile, the retail segment of the market is growing and the segment purchases under the Guaranteed Volume of Free Medical Care (GOBMP) and the Compulsory Social Health Insurance (CSHI) system are reducing slightly.

Thus, the pharmaceutical market is returning to normal consumption of drugs after the shock demand observed in the first year of the pandemic

It should be noted that among all the countries of the post-Soviet space, Kazakhstan is the leader in terms of the volume of drug provision provided at the expense of the guaranteed volume of medical care and the compulsory health insurance system. However, the retail segment accounts for 61% of the total market volume (both in tenge and dollars) and 83% in real terms. 

PharmXplorer estimates that in 2022, Kazakhstan's pharmacy network sold 513 million packages of medicines, down 0.4% from last year. Value-wise, sales increased in both tenge and dollars.

In 2022, the commercial segment accounted for 527 billion tenge or 1,145 million US dollars, a 9.4% and 1.2% increase over 2021. According to PharmXplorer inflation (7.9%) is largely responsible for the increase in the retail segment in monetary terms.

It is noteworthy that the contribution of innovations and the increase in the replacement index are noted. That is, innovative drugs are brought to the market, as before, but at the same time, the population is increasingly opting for cheaper generics and analogues.  

According to monetary consumption of drugs in ATC groups of the 1st level in the retail market segment, digestive, respiratory, nervous, cardiovascular, and antimicrobial drugs ranked highest.

At the same time in the last two months of the year there was a significant increase in sales of antimicrobial agents and drugs for the treatment of respiratory diseases, which, of course, is associated with an increase in the incidence of acute respiratory viral infections.

Leadership in the retail market in terms of sales in terms of money belongs to the domestic company #SANTO. The top 10 also includes another Kazakh manufacturer - #NOBEL Almaty. This is a very positive trend, indicating that domestic companies are actively developing not only in the state, but also in the retail sector, which means import substitution is active.

It is noteworthy that sales of drugs intended for the treatment of diseases of the digestive system remain consistently high in the commercial segment.

In the ranking of trade names in retail, #creon occupies the top spot in terms of value sales, followed by Ethyl Alcohol and #heptral.

 The maximum increase in sales in 2022 was demonstrated by #nimesil.

https://pharm.reviews/analitika/item/8086-proxima-research-international-predstavila-itogi-razvitiya-farmrynka-kazakhstana-za-2022-g